Literature DB >> 10213238

Effects of trauma and infection on ciprofloxacin levels in the vitreous cavity.

F Oztürk1, S Kortunay, E Kurt, S S Ilker, U U Inan, N E Basci, A Bozkurt, O Kayaalp.   

Abstract

OBJECTIVE: This study was designed to determine the effects of trauma and infection on vitreous ciprofloxacin levels after intravitreal injection of ciprofloxacin in rabbits.
METHODS: A penetrating injury was made in the right eyes of 24 rabbits. In the eyes of half of the traumatized animals, a standardized intraocular infection was induced by intravitreal injection of a suspension of Staphylococcus aureus. The intact left eyes of the traumatized group were maintained as controls. Ciprofloxacin (200 microg/0.1 mL) was injected into the midvitreous cavity of both eyes in all animals and samples were obtained at 2, 8, 24, and 48 hours after injection. Drug concentrations were measured using high-pressure liquid chromatography analysis.
RESULTS: At the second hour, the mean vitreous concentration of ciprofloxacin in the traumatized eyes was lower than that in control eyes (P<0.05). The mean ciprofloxacin concentrations were significantly higher (P<0.05) in the traumatized-infected eyes than were those in control or traumatized eyes at 24 and 48 hours. The elimination half-life of ciprofloxacin in control and traumatized eyes was 6.02 hours and 5.02 hours, respectively, and infection prolonged the half-life to 15.06 hours. Vitreous levels of ciprofloxacin were above the minimum inhibitory concentration (MIC90) for most of the common microorganisms causing endophthalmitis in all groups at 2 and 8 hours, but also at 24 and 48 hours in traumatized-infected eyes.
CONCLUSION: Infection appears to decrease the clearance of ciprofloxacin. Therapeutic drug levels in traumatized-infected eyes were maintained up to 48 hours. Assuming that the animal model used may have a predictive value for the drug elimination in traumatized-infected human eyes, we suggest that local administration of ciprofloxacin every 2 days may be relevant from the therapeutic perspective.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213238     DOI: 10.1097/00006982-199902000-00007

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Intravitreal clearance of moxifloxacin.

Authors:  Mohan N Iyer; Feng He; Theodore G Wensel; William F Mieler; Matthew S Benz; Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 2.  Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.

Authors:  Aniruddha Amrite; Vidya Pugazhenthi; Narayan Cheruvu; Uday Kompella
Journal:  Expert Opin Drug Deliv       Date:  2010-05       Impact factor: 6.648

3.  Subretinal fluid levels of topical, oral, and combined administered ciprofloxacin in humans.

Authors:  O Cekiç; C Batman; U Yaşar; N E Başci; O Zilelioğlu; A Bozkurt
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

4.  Effect of diabetes on transscleral delivery of celecoxib.

Authors:  Narayan P S Cheruvu; Aniruddha C Amrite; Uday B Kompella
Journal:  Pharm Res       Date:  2008-11-06       Impact factor: 4.200

Review 5.  Pharmacokinetics of intravitreal antibiotics in endophthalmitis.

Authors:  Medikonda Radhika; Kopal Mithal; Abhishek Bawdekar; Vivek Dave; Animesh Jindal; Nidhi Relhan; Thomas Albini; Avinash Pathengay; Harry W Flynn
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-09-10

Review 6.  Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis.

Authors:  Andrea Luaces-Rodríguez; Miguel González-Barcia; María José Blanco-Teijeiro; María Gil-Martínez; Francisco Gonzalez; Francisco Gómez-Ulla; María-Jesús Lamas; Francisco-Javier Otero-Espinar; Anxo Fernández-Ferreiro
Journal:  Pharmaceutics       Date:  2018-05-29       Impact factor: 6.321

7.  Intravitreal moxifloxacin injections in acute post-cataract surgery endophthalmitis: Efficacy and safety.

Authors:  Abhishek Agarwal; Manisha Nagpal
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.